In primary prevention, at what estimated 10-year ASCVD risk should statin therapy begin according to guidelines?

In primary prevention, at what estimated 10-year ASCVD risk should statin therapy begin according to guidelines?

• A. Moderate- or high-intensity statin therapy.
• B. Niacin and fibrate therapy do not have a demonstrable impact on cardiovascular outcomes.
• C. PCSK9 inhibitors (Evolocumab) are also not yet recommended in any guideline.
• D. No statin therapy.

Answer: (A)

The key idea is that statin therapy for primary prevention is guided by estimated 10-year ASCVD risk. Guidelines recommend starting moderate- to high-intensity statin therapy when the 10-year risk is elevated—typically around 7.5% or higher—so that those at greater risk receive lipid-lowering benefits to reduce first-time cardiovascular events. The exact intensity is chosen based on how high the risk is and other factors, with higher risk or additional risk enhancers often warrant high-intensity statin. In contrast, therapies like niacin or fibrates haven’t shown outcome benefits as add-ons to statins in primary prevention, PCSK9 inhibitors are not first-line for everyone and are reserved for specific high-risk scenarios or intolerance, and saying no statin would miss the guideline-supported approach for those with elevated risk. So initiating at least moderate-intensity statin therapy once the estimated 10-year ASCVD risk is elevated best fits current guidelines.

The key idea is that statin therapy for primary prevention is guided by estimated 10-year ASCVD risk. Guidelines recommend starting moderate- to high-intensity statin therapy when the 10-year risk is elevated—typically around 7.5% or higher—so that those at greater risk receive lipid-lowering benefits to reduce first-time cardiovascular events. The exact intensity is chosen based on how high the risk is and other factors, with higher risk or additional risk enhancers often warrant high-intensity statin. In contrast, therapies like niacin or fibrates haven’t shown outcome benefits as add-ons to statins in primary prevention, PCSK9 inhibitors are not first-line for everyone and are reserved for specific high-risk scenarios or intolerance, and saying no statin would miss the guideline-supported approach for those with elevated risk. So initiating at least moderate-intensity statin therapy once the estimated 10-year ASCVD risk is elevated best fits current guidelines.